•  
  •  
 

Central Asian Journal of Medicine

Abstract

The screening and treatment of hepatocellular carcinoma, the symptoms of which are usually non-specific, is considered. Patients with a high risk of developing hepatocellular carcinoma recommended determining the level of α-fetoprotein and ultrasound. However, an increase in the level of α-fetoprotein is not always characteristic of hepatocellular liver cancer and, on the contrary; its elevated levels do not always indicate primary liver cancer.

First Page

65

Last Page

79

References

1. Arif-Tiwari H., Kalb B., Chundru S. et al. MRI of hepatocellular carcinoma: an update of current practices // Diagn. Interv. Radiol. – 2014. – Vol. 20. P. 209-221. 2. Baek Y.H., Lee J.H., Jang J.S. et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP // Hepatogastroenterology. – 2009. – Vol. 56. – P. 763-767. 3. Bolondi L., Gaiani S., Celli N. et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma // Hepatology. – 2005. – Vol. 42, №1. – P. 27-34. 4. Davila J.A., Morgan R.O., Shaib Y. et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study // Gastroenterology. – 2004. – Vol. 127, №5. – P. 1372-1380. 5. Hassan M.M., Hwang L.Y., Hatten C.J. et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus // Hepatology. – 2002. – Vol. 36, №5. – P. 1206-1213. 6. Hayashi P.H., Trotter J.F., Forman L. et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD // Liver Transpl. – 2004. – Vol. 10, №1. – P. 42-48. 7. Jiang L., Cheng Q., Zhang B.H. et al. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China // Medicine (Baltimore). – 2015. – Vol. 94, №10. – P. e603. 8. Kobayashi M., Hosaka T., Ikeda K. et al. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively // Hepatol. Res. – 2011. – Vol. 41. – P. 1036-1045. 9. Liu A. M., Yao T.J., Wang W. et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study // Brit. Med. J. Open. – 2012. – Vol. 2, №2. – P. e000825. 10. Llovet Jm., Ricci S., Mazzaferro V. et al. Sorafenib in advanced hepatocellularcarcinoma // New Engl. J. Med. – 2008. – Vol. 359. – P. 378-390. 11. Morgan R.L., Baack B., Smith B.D. et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies // Ann. Int. Med. – 2013. – Vol. 158 (5 Pt 1). – P. 329-337. 12. Scoazec J.Y., Labadie M., Dumortier J., Valette P.J. Synopsis. Diagnosis of liver nodules: techniques, approach and main practical problems // Gastroenterol. Clin. Biol. – 2000. – Vol. 24, №11. – P. 1095-1103. 13. Shen Y.C., Hsu C., Cheng C.C. et al. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression // Oncology. – 2012. – Vol. 82, №5. – P. 275-289. 14. Sigal A., Volk M.L., Waljee A. et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis // Aliment. Pharmacol. Ther. – 2009. – Vol. 30. – P. 37-47. 15. Simonetti R.G., Cammа C., Fiorello F. et al. Hepatocellular carcinoma. A worldwide problem and the major risk factors // Dig. Dis. Sci. – 1991. – Vol. 36, №7. – P. 962-972. 16. Singal A.G., Conjeevaram H.S., Volk M.L. et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis // Cancer Epidemiol. Biomark. Prev. – 2012. – Vol. 21. – P. 793-799. 17. Spangenberg Hc., Mohr L., Blum He. Regional therapy of liver tumors // Internist (Berl.). – 2007. – Vol. 48. – Р. 40-45. 18. Yamamoto K., Imamura H., Matsuyama Y. et al. AFP, AFP-L3, DCP and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC // J. Gastroenterol. – 2010. –Vol. 45. – P. 1272-1282. 19. Yoshida H., Shiratori Y., Moriyama M. et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy // Ann. Int. Med. – 1999. – Vol. 131, №3. – P. 174-181.

Share

COinS